Why Is Ironwood (IRWD) Down 18.4% Since Last Earnings Report?

Company Overview - Ironwood Pharmaceuticals (IRWD) shares have decreased by approximately 18.4% over the past month, underperforming the S&P 500 [1] - The most recent earnings report is crucial for understanding the catalysts affecting the stock [1] Earnings Estimates - Fresh estimates for Ironwood have remained flat over the past month, with the consensus estimate shifting by -180% [2] VGM Scores - Ironwood has a Growth Score of B, a Momentum Score of F, and a Value Score of A, placing it in the top quintile for value investment strategy [3] - The aggregate VGM Score for Ironwood is A, which is significant for investors not focused on a single strategy [3] Outlook - Ironwood holds a Zacks Rank of 3 (Hold), indicating an expectation of in-line returns in the upcoming months [4] Industry Performance - Ironwood is part of the Zacks Medical - Drugs industry, where competitor Zoetis (ZTS) has seen a gain of 4.3% over the past month [5] - Zoetis reported revenues of $2.22 billion for the last quarter, reflecting a year-over-year increase of 1.4%, with EPS rising from $1.38 to $1.48 [5] - For the current quarter, Zoetis is projected to post earnings of $1.61 per share, indicating a year-over-year change of +3.2% [6] - The Zacks Consensus Estimate for Zoetis has changed by +1% over the last 30 days, also holding a Zacks Rank of 3 (Hold) [6]